How caspase-8 and N4BP1 control inflammation
Regulation of Proinflammatory Cytokine Responses by a Caspase-8-N4BP1 Axis
This work looks at how two proteins, caspase-8 and N4BP1, shape inflammatory signals that matter for people with immune disorders like ALPS.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11169882 on NIH RePORTER |
What this research studies
If you or a loved one has an immune disorder such as ALPS, this project explains a cellular switch that can turn inflammation up or down. Researchers use lab-grown immune cells and genetic models to remove or change caspase-8 and N4BP1 and then measure cytokine (inflammatory signal) responses to different immune triggers. They compare cells lacking caspase-8 with cells where N4BP1 is also deleted to see which inflammatory responses normalize or become exaggerated. The goal is to map this control pathway so future therapies might target it to reduce harmful inflammation or correct immune defects.
Who could benefit from this research
Good fit: People with autoimmune lymphoproliferative syndrome (ALPS) or known caspase-8/FADD mutations, and patients with unexplained immune dysregulation, would be the most relevant for this work.
Not a fit: Patients with unrelated non-immune conditions or those seeking an immediate clinical treatment are unlikely to benefit directly from this basic laboratory research.
Why it matters
Potential benefit: Could reveal new molecular targets to reduce excessive inflammation or help correct immune defects in conditions like ALPS.
How similar studies have performed: Prior lab studies have shown caspase-8 and N4BP1 affect cytokine responses, so this project builds on promising early findings rather than on established therapies.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Gitlin, Alexander — Sloan-Kettering Inst Can Research
- Study coordinator: Gitlin, Alexander
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.